Phosphatidylserine
RCTs in older adults with memory complaints or mild cognitive impairment report memory benefits, though often only in subgroups: soy PS at 100–300mg/day for 6 months helped only participants with low baseline scores (Kato-Kataoka 2010), and marine PS-DHA at 300mg/day improved immediate verbal recall in an exploratory 15-week trial (Vakhapova 2010). A 2026 network meta-analysis in MCI/Alzheimer's found PS 100mg improved MMSE but not the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog). In healthy children, a 12-week RCT of 100mg sunflower PS found no effect on primary or secondary outcomes (Friling 2025; authors include staff of IFF, the product's manufacturer). A positive 2024 MCI trial (Duan 2024; BYHEALTH co-authors) gave only 31.5mg PS inside a multi-ingredient formula. The FDA allows only a qualified claim that it may reduce the risk of dementia or cognitive dysfunction in the elderly, with the disclaimer that 'FDA concludes that there is little scientific evidence supporting this claim' (FDA letter, 13 May 2003).
Evidence reviewed:
Mechanism of action
Phosphatidylserine (PS) is a phospholipid that forms a critical component of neuronal cell membranes. It supports signal transduction across synapses, facilitates acetylcholine and dopamine release, and modulates cortisol secretion. Supplementation replenishes PS levels that decline naturally with age.
Clinical evidence summary
RCTs in older adults with memory complaints or mild cognitive impairment report memory benefits, though often only in subgroups: soy PS at 100–300mg/day for 6 months helped only participants with low baseline scores (Kato-Kataoka 2010), and marine PS-DHA at 300mg/day improved immediate verbal recall in an exploratory 15-week trial (Vakhapova 2010). A 2026 network meta-analysis in MCI/Alzheimer's found PS 100mg improved MMSE but not the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog). In healthy children, a 12-week RCT of 100mg sunflower PS found no effect on primary or secondary outcomes (Friling 2025; authors include staff of IFF, the product's manufacturer). A positive 2024 MCI trial (Duan 2024; BYHEALTH co-authors) gave only 31.5mg PS inside a multi-ingredient formula. The FDA allows only a qualified claim that it may reduce the risk of dementia or cognitive dysfunction in the elderly, with the disclaimer that 'FDA concludes that there is little scientific evidence supporting this claim' (FDA letter, 13 May 2003).
Human effect matrix
Based on human clinical trials only. Animal and in-vitro data excluded.
| Effect | Evidence | Magnitude | Studies |
|---|---|---|---|
| Memory Recall | strong | Moderate | 4 |
| Cortisol Reduction | moderate | Moderate | — |
| Processing Speed | moderate | Small | — |
| Age-Related Cognitive Decline | moderate | Small | 1 |
Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results
Documented benefits
- Memory recall in older adults with memory complaints (often subgroup-only)
- MMSE scores in MCI/Alzheimer's (network meta-analysis)
- Cortisol reduction under stress (not re-verified in our 2026 review)
Side effects & cautions
- Well tolerated — no safety differences versus placebo over 15 weeks at 300mg/day
- Mild GI discomfort in some users
- Open-label 100mg/day extension: small drop in resting diastolic blood pressure and slight weight gain
How to take
Stacking recommendations
Ingredients that pair well with Phosphatidylserine and why.
PS maintains cell membrane integrity while Lion's Mane drives NGF synthesis. Both support long-term brain health via complementary structural and growth-factor pathways.
Both are membrane phospholipid precursors, but they work on different pathways. Citicoline primarily builds phosphatidylcholine; PS addresses phosphatidylserine. Together they provide comprehensive neuronal membrane support.
DHA is a structural component of neuronal membranes. Some clinical PS products are DHA-conjugated (PS-DHA): a 15-week trial of marine PS-DHA at 300mg/day improved immediate verbal recall in older adults with memory complaints.
Frequently asked questions
Soy-derived vs sunflower PS — which is better?
Both are used in trials: soy PS in older adults with memory complaints (Kato-Kataoka 2010) and sunflower PS in healthy children, where it had no effect (Friling 2025). Sunflower-derived PS is soy-free and is the preferred option for anyone with soy sensitivity. No head-to-head comparison of the two was part of our 2026 review.
What is the FDA health claim for PS?
The FDA allows only a qualified claim that phosphatidylserine may reduce the risk of dementia or cognitive dysfunction in the elderly, with the disclaimer that 'FDA concludes that there is little scientific evidence supporting this claim' (FDA letter, 13 May 2003). The claim wording itself says that 'very limited and preliminary scientific research suggests' this.
What about the bovine brain source I see mentioned in older studies?
Original 1990s PS trials used bovine-cortex-derived PS. This source was discontinued globally after BSE (mad cow disease) concerns. All current commercial PS is plant- or marine-derived. The later plant- and marine-PS trials show memory benefits mainly in subgroups of older adults, so the older bovine results should not be assumed to transfer.
Does PS interact with blood thinners?
No clinical interaction between PS and anticoagulants was found in our 2026 PubMed review, and the main PS safety trial did not collect bleeding data. If you are on warfarin, aspirin, or other anticoagulants, consult your doctor before adding any supplement.
Top stacks containing Phosphatidylserine
Phosphatidylserine in Australia
Phosphatidylserine (PS) is listed in Australia's Therapeutic Goods (Permissible Ingredients) Determination as 'soy phosphatidylserine-enriched soy lecithin': a liquid at Schedule 1 item 4689 and a powder at item 4690, each with purpose code A (active ingredient). Both entries make soy phosphatidylserine a mandatory component and state that the maximum recommended daily dose of the medicine must not provide more than 300 mg of soy phosphatidylserine. The Therapeutic Goods Administration (TGA) says that if an ingredient isn't listed in the Determination, it can't be used in listed or assessed listed medicines; items 4689 and 4690 are the entries we found under the name 'phosphatidylserine' in Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940), checked 2026-10-08.
What the two phosphatidylserine entries require
Items 4689 (liquid) and 4690 (powder) of Schedule 1 carry the same two requirements: soy phosphatidylserine is a mandatory component of the ingredient, and 'the maximum recommended daily dose of the medicine must not provide more than 300 mg of soy phosphatidylserine.' The requirements column for each entry lists nothing else -- no sponsor-exclusivity clause of the kind attached to citicoline's entry (item 1428) and no label warning statement of the kind theanine's entry (item 4911) requires.
Products in Australia
- Mind Lab Pro7.5/10Personal Importation SchemeLocal price: ≈ $89/month
- Qualia Mind7.3/10Personal Importation SchemeLocal price: USD 159 · 1 x Qualia Mind 2.0 - 120 count Boxed
- Hunter Focus6.3/10Personal Importation Scheme
TGA (AUST L)
Is phosphatidylserine a permitted ingredient in Australian listed medicines?
Yes, as soy phosphatidylserine-enriched soy lecithin. Schedule 1 of the Permissible Ingredients Determination lists it as a liquid (item 4689) and a powder (item 4690) for use as an active ingredient, with no more than 300 mg of soy phosphatidylserine in the medicine's maximum recommended daily dose (checked 2026-10-08).
State & territory guides
Sources: Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, item 4689 (Soy phosphatidylserine-enriched soy lecithin liquid) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, item 4690 (Soy phosphatidylserine-enriched soy lecithin powder) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, items 4689 and 4690 (dose cap) · TGA -- Permissible ingredients determination (overview)
Regulatory note
Therapeutic goods available in Australia are regulated by the Therapeutic Goods Administration (TGA). AUST L–listed products carry pre-approved permitted indications; AUST R–registered products are higher-evidence. Imported products without TGA listing are not assessed by Australian regulators. This page is editorial, not promotional, and does not constitute medical advice. Always read the label and follow directions for use. Consult a qualified healthcare professional before starting any supplement.
Sources (6)expand
- PMID 21103034Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. (2010)
- PMID 20523044Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. (2010)
- PMID 21711517Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension. (2011)
- PMID 39317299Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial. (2024)
- PMID 41318468The cognitive effects of supplementation with sunflower phosphatidyl serine in healthy children aged 8 to 12 years: a randomized controlled trial. (2025)
- PMID 42494057The impact of supplements on cognitive function for Alzheimer's disease or mild cognitive impairment: a systematic review and network meta-analysis. (2026)